13D Filing: Versant Venture Capital IV, L.P. and Crispr Therapeutics AG (CRSP)

 

Explanatory Note:    This statement on Schedule 13D (the Schedule 13D) constitutes Amendment No. 1 solely on behalf of, and to the extent that it relates to the Schedule 13D initially filed by the Reporting Persons with the U.S. Securities and Exchange Commission on November 3, 2016 (the Original Filing).  Except to the extent specifically set forth herein, the information in the Original Filing remains true and accurate with respect to the Reporting Persons.

 

Item 4.   Purpose of Transaction

 

Solely on behalf of, and only to the extent that it relates to, the Reporting Persons, Item 4 of the Original Filing is hereby amended and supplemented by the addition of the following:

 

On September 5, 2017, (i) VVC IV distributed 1,368,013 shares of Common Stock to its partners; (ii) VSF IV distributed 8,110 shares of Common Stock to its partners; (iii) VVC V distributed 814,599 shares of Common Stock to its partners; (iv) VAF V distributed 23,899 shares of Common Stock to its partners; (v) VV V CAN distributed 61,993 shares of Common Stock to its partners; and (vi) VOA distributed 26,491 shares of Common Stock to its partners, all for no additional consideration.

 

On September 5, 2017, VV IV received 292,529 shares of Common Stock from an in-kind distribution from VVC IV for no additional consideration. On September 5, 2017, VV IV distributed 292,529 shares of Common Stock to its members for no additional consideration.

 

On September 5, 2017, VV V received (i) 16,291 shares of Common Stock from an in-kind distribution from VVC V; (ii) 471 shares of Common Stock from an in-kind distribution from VAF V; and (iii) 521 shares of Common Stock from an in-kind distribution from VOA for no additional consideration.  On September 5, 2017, VV V distributed 17,283 shares of Common Stock to its members for no additional consideration.

 

On September 5, 2017, VV V CAN received 1,240 shares of Common Stock from an in-kind distribution from VVC CAN for no additional consideration.  On September 5, 2017, VV V CAN distributed 1,240 shares of Common Stock to its partners for no additional consideration.

 

12